

# Author Index for Volume 11

- Adachi JD, 88  
 Ahn S, 287  
 Alexander S, 256  
 Anderson GD, 294  
 Anderson RJ, 285  
 Apolone G, 291  
 Azen S, 275, 299, 314
- Bailey G, 286, 287  
 Baker SA, 257  
 Baliker J, 281  
 Barlow B, 275  
 Barlow W, 314  
 Barwick JA, 180  
 Begg CB, 223  
 Benichou J, 266  
 Berge KG, 267  
 Bénichou J, 282  
 Bingham SF, 292  
 Blackwelder WC, 187  
 Blackhurst DW, 287, 376  
 Blajachman M, 268  
 Blafox MD, 274  
 Boichot H, 287  
 Boissel J-P, 257, 300  
 Boone DC, 305  
 Borhani N, 287  
 Borhani P, 286, 287  
 Bosch EG, 296  
 Bresnick G, 281  
 Bridgers S, 307  
 Brittain E, 329  
 Brokschmidt JK, 277  
 Brown E, 298  
 Brown MW, 277  
 Brownscombe I, 281  
 Buchwald H, 217  
 Buekens P, 256  
 Bull S, 268  
 Burack RC, 285  
 Burdick E, 341  
 Burg G, 283  
 Burroughs J, 273  
 Buyse M, 265, 270  
 Byar D, 129  
 Byington RP, 286, 289
- Cairns J, 276  
 Califf R, 268, 284  
 Callahan D, 402
- Canadian Cooperative MS  
 Study Group, The, 260
- Carew B, 287  
 Carlow JJ, 282  
 Carmody S, 286  
 Carr MA, 271  
 Case LD, 261  
 Cashin-Hemphill L, 299  
 CAST Investigators, The,  
 274, 285, 306
- Cataldo G, 420  
 Chalmers TC, 341  
 Chappell R, 257  
 Chastang C, 266, 282  
 Chauvin F, 300  
 Chernug N, 273  
 Cheuvart B, 265  
 Cheveret S, 254, 282  
 Christiansen DH, 101  
 Clark KF, 304  
 Clifford C, 129  
 Cline DR, 280, 307  
 Cnaan A, 265, 270  
 Cohen H, 268, 284  
 Cohen J, 267  
 Cohen N, 199  
 Collet J-P, 257  
 Colling CL, 260  
 Collins D, 293  
 Collins JF, 292  
 Connett JE, 24, 273  
 Connolly S, 288  
 Connor PB, 272  
 Copeland J, 259  
 Cosgrove N, 256, 287  
 Costantini L, 276  
 Cross AP, 253  
 Crouse JR, 277  
 Crow S, 271  
 Cutler J, 274
- Dain BJ, 261  
 Dannenberg AL, 101  
 Davey J, 256  
 Davis BR, 267, 274  
 Davis CE, 37  
 Day PL, 260  
 Deber RB, 355  
 Deloria MA, 187  
 De Rosa M, 292
- Deveshwar R, 298  
 Dickens K, 52, 255  
 Dierenfeldt B, 287  
 Dies F, 286  
 Dietrich K, 298  
 Dimenäs E, 169  
 Dolan N, 287  
 Donithan M, 279  
 Drabik MJ, 271  
 Dupont WD, 116, 301
- Easterbrook PJ, 308  
 Eberly S, 284  
 Edens T, 287  
 Edwards B, 433  
 Eisenberg MS, 295  
 Ellenberg JH, 260  
 Ellenberg SS, 80  
 Elsinger JE, 180  
 Emerson JD, 341  
 Engelhard M, 283  
 Espeland MA, 261, 263  
 Evans GW, 261, 277  
 Evans P, 304  
 Ezekowitz M, 307
- Feeny D, 267  
 Feinman V, 268  
 Fetting JH, 307  
 Fink NE, 290  
 Finkelstein D, 80  
 Fisher MR, 376  
 Fisher SG, 199  
 Fletcher B, 300  
 Fletcher G, 300  
 Forsythe AB, 80  
 Foulkes MA, 180  
 France LA, 266  
 Freedman LS, 80, 157, 254,  
 269  
 Freeman K, 80  
 Furlong B, 267  
 Fye CL, 260
- Ganguly A, 281  
 Gassman JJ, 271  
 Gatsonis CA, 253  
 Gent M, 259, 260, 276, 279,  
 280, 283, 288  
 Gill J, 276

- Gillespie MJ, 272  
 Gimotty P, 285  
 Giro R, 294  
 Glover FN, 278  
 Goldman S, 129, 259  
 Gonzales CR, 286  
 Goodlow JL, 273  
 Goodwin L, 286, 287  
 Gorbach SL, 129  
 Gordon ME, 273  
 Gould AL, 264  
 Green SB, 80  
 Greene HL, 285  
 Greenhouse JB, 253, 258  
 Grill R, 291  
 Grimes D, 290  
 Grimm R, 267  
 Grubb SC, 272  
 Guill M, 433  
 Guin J, 433  
 Guthrie D, 255  
 Guyatt GH, 43, 88  
  
 Haakenson C, 260, 72, 302  
 Hagerty C, 297  
 Hale C, 306  
 Hall J, 295  
 Hall WJ, 264  
 Hallstrom AP, 274, 85, 295, 305  
 Hannah ME, 283  
 Harrelson-Woodlief L, 268, 284  
 Harrington J, 286  
 Hartigan PM, 266  
 Hartman A, 433  
 Hasford J, 297  
 Hastings BK, 187  
 Hawkins BS, 273, 287, 376  
 Hawkins CM, 267, 274  
 Helms RW, 7  
 Henderson M, 129  
 Henderson W, 259  
 Henderson WG, 199, 291  
 Hewson SA, 283  
 Heyting A, 88  
 Higgins K, 52  
 Hill AB, 77  
 Hill LR, 297  
 Hill M, 287  
 Hilner JE, 15  
 Hirtz DG, 260  
 Hlatky M, 268  
 Ho MT, 295  
 Hoaglin DC, 341  
 Hoffmeier M, 287  
 Hosking JD, 101  
 Howard G, 277, 303  
  
 Hughes MD, 254  
 Hursh D, 271  
 Huther M, 285  
  
 Insull W, 129  
 Iso-BCC Study Group, The, 433  
 Iverson D, 129  
  
 Jaeschke R, 43, 88  
 James B, 270  
 James KE, 307  
 Jeffery R, 262  
 Jeffreys JL, 290  
 Jensen J, 256  
 Johnson A, 286  
 Johnson P, 286  
 Johnston DB, 306  
 Jones M, 286  
 Jones MS, 302, 303, 398  
 Julian D, 279  
  
 Kalish LA, 147  
 Karnash S, 284  
 Kay R, 266  
 Keller J, 88  
 Kessler L, 129  
 Kestle JRW, 299  
 Khatir S, 272  
 Kim K, 265  
 Kocourek J, 306  
 Korn EL, 67  
 Koski B, 304  
 Kostis J, 287  
 Krakoff IH, 278  
 Kraska EW, 277  
 Krieger S, 287  
 Krol WF, 292  
 Kudenchuk PJ, 295  
 Kuller LH, 267  
  
 La Chance P-A, 295  
 Lachin JM, 150  
 Lai M-Y, 275  
 Laird NM, 296, 405  
 Langford HG, 274  
 Laupacis A, 281, 288  
 Leatherman JL, 271  
 Lee J, 300  
 Lee K, 284  
 Lee KK, 302  
 Lee MLF, 187  
 Lee YJ, 260  
 Leffingwell DP, 37  
 Lefkopoulou M, 80, 265  
 Leong L, 297  
 Levin J, 286  
 Levine MN, 299  
  
 Levine S, 298  
 Lewis JA, 266  
 Liberati A, 291  
 Lipscomb J, 268  
 Litchfield T, 297  
 Litwin PE, 295  
 Loomer S, 297  
 LoPresti F, 294  
  
 Machin D, 70  
 Macular Photocoagulation Study Group, The, 287  
 Maguire MG, 262, 287, 290  
 Malone LA, 272, 303, 398  
 Mann SL, 269  
 Maone LA, 302  
 Marek PM, 269  
 Margitic SE, 289  
 Mark D, 268  
 Markowitz JA, 289  
 Marsoni S, 291  
 Martin J, 271  
 Martin JS, 295  
 Marubini E, 420  
 Matts JP, 150  
 McBride R, 272  
 McCanless I, 7  
 McDermott M, 284  
 McFadden E, 270  
 McGunagle D, 282  
 MDRD Group, The, 271  
 Mebane IL, 303  
 Meinert CL, 1, 52, 255, 399  
 Melia BM, 275  
 Mellette R, 433  
 Melton J, 268  
 Menon P, 433  
 Mezzanotte G, 420  
 Miké V, 153  
 Mirenzi E, 294  
 Moher D, 290  
 Mohide P, 267  
 Monsees DM Jr, 306  
 Montoro C, 420  
 Moritz T, 259  
 Morris HF, 285  
 Moss AJ, 277  
 Mosteller F, 341  
 Muss HB, 261  
 Myles J, 274, 306  
  
 Neidhart JA, 278  
 Nelson HL, 280, 294  
 Nelson KB, 260  
 Newhouse MM, 272  
 Niland J, 297  
 Noseworthy JH, 260, 281

- Oakes D, 264, 284, 304  
 Oberman A, 274, 300  
 Orme C, 304  
 O'Quigley J, 254  
  
 Paculucci G, 292  
 Pantadosi S, 397  
 Parkinson Study Group, The,  
     264, 284, 304  
 Parmar M, 255  
 Pater J, 301  
 Paul N, 280  
 Peck G, 433  
 Peduzzi P, 263  
 Pelusio RM, 304  
 Penn ZJ, 226  
 Pession A, 292  
 Peterson AV Jr, 269  
 Petroccione A, 420  
 Petrovitch H, 286, 287  
 Pledger GW, 300  
 Plumb S, 284, 304  
 Plummer WD Jr, 116, 301  
 Pocock SJ, 254  
 Pogoda J, 299  
 Prentice R, 129  
 Prior MJ, 376  
 Probstfield J, 286, 287  
  
 Raber MN, 278  
 Rago S, 292  
 Ramadin N, 298  
 Raman S, 290  
 Renard J, 270  
 Roberts R, 260, 276, 283,  
     288  
 Roberts RS, 88, 259, 294  
 Robinson G, 267  
 Robinson J, 433  
 Rochon J, 262  
 Rogers W, 287  
 Rondelli R, 292  
 Rose LA, 277  
 Rovelli F, 420  
 Rudolph A, 304  
 Rush RL, 180  
  
 Sabella LR, 285, 291  
 Sackett DL, 299  
 Sadura A, 288  
 Sahlroot JT, 300  
 Salasche S, 433  
 Salisbury D, 258  
  
 Schaefer SM, 295  
 Schecter M, 258  
 Schneider JA, 304  
 Schoenfeld D, 80  
 Schron E, 274  
 Scott WE, 273  
 Seip A, 288  
 Self S, 129  
 Sethi G, 259  
 Severski PK, 277  
 SHEP Cooperative Study  
     Group, The, 286, 287  
 Shih WJ, 264  
 Shoulson I, 284, 304  
 Sicurella J, 259, 283, 288  
 Silicone Study Group, The,  
     305, 314  
 Silverman WA, 4  
 Siminoff LA, 307  
 Singer J, 43  
 Skinner HA, 298  
 Sliwa D, 270  
 Smith J, 256  
 Smith RP, 80  
 Smoller SW, 274  
 SOLVD Investigators, The,  
     287  
 Spadaro A, 271  
 Stangl D, 258  
 Staquet M, 270, 293  
 Steer PJ, 226  
 Stewart L, 255  
 Stoll H, 433  
 Stukel TA, 261  
 Sugars C, 286  
 Sulentic J, 300  
 Sylvester R, 215  
  
 Tandon PK, 276  
 Tangrea J, 433  
 Taylor DW, 296  
 Taylor KM, 298  
 Taylor P, 433  
 Thomas RG, 264, 280, 302  
 Thompson D, 129  
 Thompson GG, 355  
 Tietjen G, 298  
 Tilley BC, 298  
 Tomkins D, 267  
 Tonascia J, 262, 279  
 Toole JF, 277  
 Topol E, 284  
 Torrance G, 267  
  
 Torri V, 291  
 Townsend M, 267  
 Tyrrell D, 280  
  
 Unger D, 256  
 Urban N, 129  
  
 VA Cooperative Study  
     Group on Cochlear  
     Implantation, The, 199  
 Vandervoort MK, 260  
 Van Glabbeke M, 293  
 Van Natta M, 262  
 Verter J, 263, 274  
 Vogel VG, 269  
 Vogt TM, 287, 295  
 Voynick IM, 293  
  
 Wahl M, 169  
 Wald N, 309  
 Walter SD, 276  
 Waltzman S, 199  
 Wang F, 296, 405  
 Wasilauskas CH, 303  
 Watts A, 284  
 Weaver WD, 295  
 Weber L, 199  
 Wei LJ, 150  
 Weiner D, 287  
 Weiss DG, 292  
 Welch KMA, 298  
 Welch SR, 278  
 Wells HB, 303  
 Whyte J, 278  
 Wickham E, 299  
 Wiklund I, 169  
 Wilkins P, 294  
 Wilkinson P, 279  
 Williams C, 255  
 Williams OD, 101  
 Williford WO, 292  
 Willis D, 289  
 Winton G, 433  
 Wirkus MJ, 295  
 Wittes J, 267, 329  
 Wong Lee W, 24  
  
 Yetisir E, 280, 294  
  
 Zee B, 301  
 Zicarelli T, 270  
 Zimbaldi N, 274  
 Zwingers TR, 283

---

## Subject Index for Volume 11

---

### **AIDS**

Issues in the Design of Drug Trials for  
AIDS, 80

### **ANGIOGRAPHY**

A Linear Model Suitable for Assessing  
Graft Patency in Controlled Clinical  
Trials, 420

### **ATHEROSCLEROSIS**

Computer-Assisted Data Collection in  
Multicenter Epidemiologic Re-  
search, 101

### **BASAL CELL CARCINOMA**

Isotretinoin-Basal Cell Carcinoma Preven-  
tion Trial, 433

### **BASELINE CHARACTERISTICS**

Isotretinoin-Basal Cell Carcinoma Preven-  
tion Trial, 433

### **BAYESIAN METHODS**

Empirical Bayes Estimates of Subgroup  
Effects in Clinical Trials, 37  
Projection from Previous Studies: A Cau-  
tion, 67

### **BREAST CANCER**

The Effect of Partial Noncompliance on  
the Power of a Clinical Trial, 157  
Variations in Breast Cancer Treatment  
Decisions and Their Impact in  
Mounting Trials, 355

### **BREECH DELIVERY**

Reasons for Declining Participation in a  
Prospective Randomized Trial to  
Determine the Optimum Mode of  
Delivery of the Preterm Breech,  
226

### **CADC SYSTEM**

Computer-Assisted Data Collection in  
Multicenter Epidemiologic Re-  
search, 101

### **CASE-COHORT SAMPLING**

Analysis of the Costs of a Large Preven-  
tion Trial, 129

### **CASE-CONTROL STUDIES**

Power and Sample Size Calculations: A  
Review and Computer Program, 116

### **CESAREAN DELIVERY**

Reasons for Declining Participation in a  
Prospective Randomized Trial to  
Determine the Optimum Mode of  
Delivery of the Preterm Breech, 226

### **CHEMOPREVENTION**

Isotretinoin-Basal Cell Carcinoma Preven-  
tion Trial, 433

### **COEFFICIENT OF VARIATION**

Estimation of the Coefficient of Variation  
from Laboratory Analysis of Split  
Specimens for Quality Control in  
Clinical Trials, 24

### **COHORT STUDIES**

Power and Sample Size Calculations: A  
Review and Computer Program,  
116

### **COMPLIANCE**

Value of A Run-In Period in a Drug Trial  
During Pregnancy, 187

### **COMPOSITE SCORE**

Use of Principal Components Analysis to  
Develop a Composite Score as a  
Primary Outcome Variable in a  
Clinical Trial, 199

### **CONFIDENCE INTERVAL APPROACH**

Projection from Previous Studies: A Cau-  
tion, 67

### **CONFLICT OF INTEREST**

NHLBI Trials and Conflicts of Interest, 217

### **CONTINUOUS OUTCOMES**

Power and Sample Size Calculations: A  
Review and Computer Program, 116

### **CORONARY ARTERY BYPASS**

A Linear Model Suitable for Assessing  
Graft Patency in Controlled Clinical  
Trials, 420

**COSTS**

Analysis of the Costs of a Large Prevention Trial, 129

**COVARIATE IMBALANCE**

Significance Tests of Covariate Imbalance in Clinical Trials, 223

**CROSSOVERS**

The Effect of Therapeutic Treatment  
Crossovers on the Power of Clinical Trials, 314

**DATABASE MANAGEMENT SYSTEM**

Addition of an Error Correction Facility to a Functioning Data Management System, 180

**DATA COLLECTION**

Computer-Assisted Data Collection in Multicenter Epidemiologic Research, 101

**DATA EDITING**

Addition of an Error Correction Facility to a Functioning Data Management System, 180

**DICHOTOMOUS OUTCOMES**

Power and Sample Size Calculations: A Review and Computer Program, 116

**DIETARY FAT**

The Effect of Partial Noncompliance on the Power of a Clinical Trial, 157

**DISTRIBUTED DATA MANAGEMENT**

Computer-Assisted Data Collection in Multicenter Epidemiologic Research, 101

**DOUBLE-BLIND METHOD**

N of 1 Randomized Trials for Investigating New Drugs, 88

**DRUG EFFICACY**

A Linear Model Suitable for Assessing Graft Patency in Controlled Clinical Trials, 420

**DURATION OF FOLLOW-UP**

Factors of Importance When Evaluating Quality of Life in Clinical Trials, 169

**EFFICIENCY**

The Run-In Period in Clinical Trials: The Effect of Misclassification on Efficiency, 329

Value of A Run-In Period in a Drug Trial During Pregnancy, 187

**EMPIRICAL STUDY**

An Empirical Study of the Possible Relation of Treatment Differences to Quality Scores in Controlled Randomized Clinical Trials, 341

**ENROLLMENT**

Relationship Between Rate of Patient Enrollment and Quality of Clinical Center Performance in Two Multicenter Trials in Ophthalmology, 376

**ERROR CORRECTION**

Addition of an Error Correction Facility to a Functioning Data Management System, 180

**ESTIMATION**

Estimating Rates of Change in Randomized Clinical Trials, 405

**ETHICS**

Ethics, Evidence, and Uncertainty, 153

**EVIDENCE**

Ethics, Evidence, and Uncertainty, 153

**FREQUENTIST APPROACH**

Projection from Previous Studies: A Caution, 67

**GRAFT PATENCY**

A Linear Model Suitable for Assessing Graft Patency in Controlled Clinical Trials, 420

**HAZARD FUNCTION**

A Linear Model Suitable for Assessing Graft Patency in Controlled Clinical Trials, 420

**HEARING LOSS**

Use of Principal Components Analysis to Develop a Composite Score as a Primary Outcome Variable in a Clinical Trial, 199

**HIERARCHICAL STRUCTURE**

The Conflict Between Relational Databases and the Hierarchical Structure of Clinical Trials Data, 7  
The Seeds of Dualism in Medical Research, 4

**HIV INFECTION**

Issues in the Design of Drug Trials for AIDS, 80

**ISOTRETINOIN**

Isotretinoin-Basal Cell Carcinoma Prevention Trial, 433

**LINEAR MODEL**

A Linear Model Suitable for Assessing Graft Patency in Controlled Clinical Trials, 420

**LOW-TECH TRIALS**

Issues in the Design of Drug Trials for AIDS, 80

**MAXIMUM LIKELIHOOD ESTIMATE**

Estimation of the Coefficient of Variation from Laboratory Analysis of Split Specimens for Quality Control in Clinical Trials, 24

Projection from Previous Studies: A Caution, 67

**MEASUREMENT**

A Comparison of Seven-Point and Visual Analogue Scales, 43

**MEDLINE**

Identification of Meta-Analyses: The Need for Standard Terminology, 52

**META-ANALYSIS**

Identification of Meta-Analyses: The Need for Standard Terminology, 52

**MISCLASSIFICATION**

The Run-In Period in Clinical Trials: The Effect of Misclassification on Efficiency, 329

**MULTICENTER TRIALS**

Isotretinoin-Basal Cell Carcinoma Prevention Trial, 433

Multicenter Trials and Travel: Luxury or Necessity?, 399

Relationship Between Rate of Patient Enrollment and Quality of Clinical Center Performance in Two Multicenter Trials in Ophthalmology, 376

**MULTIVARIATE APPROACH**

Estimating Rates of Change in Randomized Clinical Trials, 405

**NEW DRUGS**

N of 1 Randomized Trials for Investigating

New Drugs, 88

**NONCOMPLIANCE**

The Effect of Partial Noncompliance on the Power of a Clinical Trial, 157

**OUTCOME VARIABLE**

Use of Principal Components Analysis to Develop a Composite Score as a Primary Outcome Variable in a Clinical Trial, 199

**PERMUTATION TESTS**

Permutation Tests Following Restricted Randomization Procedures, 147, 150

**PHASE II TRIALS**

N of 1 Randomized Trials for Investigating New Drugs, 88

**PLACEBO**

Factors of Importance When Evaluating Quality of Life in Clinical Trials, 169

Isotretinoin-Basal Cell Carcinoma Prevention Trial, 433

Value of A Run-In Period in a Drug Trial During Pregnancy, 187

**POOLING OF RESULTS**

Identification of Meta-Analyses: The Need for Standard Terminology, 52

**POSTRANDOMIZATION**

Estimating Rates of Change in Randomized Clinical Trials, 405

**POWER**

The Effect of Partial Noncompliance on the Power of a Clinical Trial, 157

The Effect of Therapeutic Treatment Crossovers on the Power of Clinical Trials, 314

Power and Sample Size Calculations: A Review and Computer Program, 116

Value of A Run-In Period in a Drug Trial During Pregnancy, 187

**PREGNANCY**

Reasons for Declining Participation in a Prospective Randomized Trial to Determine the Optimum Mode of Delivery of the Preterm Breech, 226

Value of A Run-In Period in a Drug Trial During Pregnancy, 187

**PREMATURITY**

Reasons for Declining Participation in a



- Prospective Randomized Trial to Determine the Optimum Mode of Delivery of the Preterm Breech, 226
- Value of A Run-In Period in a Drug Trial During Pregnancy, 187

#### **PRERANDOMIZATION**

- Value of A Run-In Period in a Drug Trial During Pregnancy, 187

#### **PREVENTION TRIALS**

- Analysis of the Costs of a Large Prevention Trial, 129
- Does Taking Extra Vitamins Prevent Spina Bifida?, 309
- The Effect of Partial Noncompliance on the Power of a Clinical Trial, 157
- Isotretinoin-Basal Cell Carcinoma Prevention Trial, 433

#### **PRINCIPAL COMPONENTS**

- Use of Principal Components Analysis to Develop a Composite Score as a Primary Outcome Variable in a Clinical Trial, 199

#### **PROJECTION**

- Projection from Previous Studies: A Caution, 67

#### **QUALITY CONTROL**

- Computer-Assisted Data Collection in Multicenter Epidemiologic Research, 101
- An Empirical Study of the Possible Relation of Treatment Differences to Quality Scores in Controlled Randomized Clinical Trials, 341
- Estimation of the Coefficient of Variation from Laboratory Analysis of Split Specimens for Quality Control in Clinical Trials, 24
- Relationship Between Rate of Patient Enrollment and Quality of Clinical Center Performance in Two Multicenter Trials in Ophthalmology, 376

#### **QUALITY OF LIFE**

- Assessing Technology for the Long-Run, 402
- A Comparison of Seven-Point and Visual Analogue Scales, 43
- Factors of Importance When Evaluating Quality of Life in Clinical Trials, 169

#### **QUANTITATIVE SYNTHESIS**

- Identification of Meta-Analyses: The Need for Standard Terminology, 52

#### **RANDOM ALLOCATION**

- N of 1 Randomized Trials for Investigating New Drugs, 88

#### **RANDOMIZATION PROCEDURES**

- Permutation Tests Following Restricted Randomization Procedures, 147, 150

#### **RANDOMIZED TRIALS**

- A Comparison of Seven-Point and Visual Analogue Scales, 43
- An Empirical Study of the Possible Relation of Treatment Differences to Quality Scores in Controlled Randomized Clinical Trials, 341
- Estimating Rates of Change in Randomized Clinical Trials, 405
- Issues in the Design of Drug Trials for AIDS, 80
- Memories of the British Streptomycin Trial in Tuberculosis: The First Randomized Clinical Trial, 77
- N of 1 Randomized Trials for Investigating New Drugs, 88
- Reasons for Declining Participation in a Prospective Randomized Trial to Determine the Optimum Mode of Delivery of the Preterm Breech, 226
- Significance Tests of Covariate Imbalance in Clinical Trials, 223

#### **RATE OF CHANGE**

- Estimating Rates of Change in Randomized Clinical Trials, 405

#### **RECRUITMENT**

- Analysis of the Costs of a Large Prevention Trial, 129
- Isotretinoin-Basal Cell Carcinoma Prevention Trial, 433

#### **RELATIONAL DATABASE SOFTWARE**

- The Conflict Between Relational Databases and the Hierarchical Structure of Clinical Trials Data, 7

#### **REMOTE DATA ENTRY**

- Computer-Assisted Data Collection in Multicenter Epidemiologic Research, 101

#### **RESPONSIVENESS**

- A Comparison of Seven-Point and Visual Analogue Scales, 43

#### **RUN-IN**

- The Run-In Period in Clinical Trials: The Effect of Misclassification on Effi-

ciency, 329

Value of A Run-In Period in a Drug Trial  
During Pregnancy, 187

#### **SAMPLE SIZE**

The Effect of Partial Noncompliance on  
the Power of a Clinical Trial, 157  
Power and Sample Size Calculations: A  
Review and Computer Program, 116

#### **SEEMINGLY UNRELATED REGRESSION**

Estimating Rates of Change in Random-  
ized Clinical Trials, 405

#### **SEVEN-POINT SCALES**

A Comparison of Seven-Point and Visual  
Analogue Scales, 43

#### **SIGNIFICANCE TESTS**

Significance Tests of Covariate Imbalance  
in Clinical Trials, 223

#### **SINGLE SUBJECT DESIGN**

N of 1 Randomized Trials for Investigating  
New Drugs, 88

#### **SPINA BIFIDA**

Does Taking Extra Vitamins Prevent Spina  
Bifida?, 309

#### **SPLIT SPECIMENS**

Estimation of the Coefficient of Variation  
from Laboratory Analysis of Split  
Specimens for Quality Control in  
Clinical Trials, 24

#### **STREPTOMYCIN TRIAL**

Memories of the British Streptomycin  
Trial in Tuberculosis: The First Ran-  
domized Clinical Trial, 77

#### **STROKE**

Addition of an Error Correction Facility to  
a Functioning Data Management  
System, 180

#### **SUBGROUP ANALYSIS**

Empirical Bayes Estimates of Subgroup  
Effects in Clinical Trials, 37

#### **SYSTEM DESIGN**

Addition of an Error Correction Facility to  
a Functioning Data Management  
System, 180

#### **TECHNOLOGY ASSESSMENT**

Assessing Technology for the Long-Run,  
402

#### **TRIAL DESIGN**

Factors of Importance When Evaluating  
Quality of Life in Clinical Trials,  
169  
Isotretinoin-Basal Cell Carcinoma Preven-  
tion Trial, 433  
Issues in the Design of Drug Trials for  
AIDS, 80

#### **UNCERTAINTY**

Ethics, Evidence, and Uncertainty, 153

#### **UNIVARIATE APPROACH**

Estimating Rates of Change in Random-  
ized Clinical Trials, 405

#### **VAGINAL INFECTIONS**

Value of A Run-In Period in a Drug Trial  
During Pregnancy, 187

#### **VARIANCE-COVARIANCE MATRIX**

Use of Principal Components Analysis to  
Develop a Composite Score as a  
Primary Outcome Variable in a  
Clinical Trial, 199

#### **VISUAL ANALOGUE SCALES**

A Comparison of Seven-Point and Visual  
Analogue Scales, 43

#### **VITAMINS**

Does Taking Extra Vitamins Prevent Spina  
Bifida?, 309



